Details

Autor(en) / Beteiligte

• Matsuoka, Hirofumi
• Nakamura, Keiichiro
• Yorimitsu, Masae
• Ogawa, Mariko
• Kanemori, Miho
• Sueoka, Kotaro
• Kozai, Ayumi
• Nakamura, Hiroko
• Haruma, Tomoko
• Shiroyama, Yuko
• Hayata, Yuu
• Sugii, Hirokazu
• Ueda, Akiko
• Kurihara, Shuichi
• Urayama, Saiko
• Shimizu, Miyuki
• Masuyama, Hisashi

Titel

Relationship Between Hematological Toxicities During Maintenance Treatment and During Chemotherapy Before Maintenance Treatment in Patients With Platinum-sensitive Relapsed Ovarian Cancer

Ist Teil von

• Anticancer research, 2023-08, Vol.43 (8), p.3653-3658

Ort / Verlag

Greece

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• To determine if maintenance treatment can be performed effectively and safely in patients with platinum-sensitive relapsed ovarian cancer. We carried out a multi-center study to investigate progression-free survival (PFS) and adverse events (AEs) in 229 patients receiving maintenance treatment for platinum-sensitive relapsed ovarian cancer. The median PFS in the 229 patients with maintenance treatment was 14.0 months (95% confidence interval=10.3-17.6 months). The hematological toxicities included ≥grade 3 anemia in 33.2% of cases. Anemia during maintenance treatment was significantly more common than anemia during chemotherapy given before maintenance treatment (p<0.001). Anemia during chemotherapy prior to maintenance treatment significantly increased the risk of anemia during maintenance treatment, compared with other clinical features (p<0.001). Maintenance treatment can be performed safely and effectively in patients with platinum-sensitive relapsed ovarian cancer. Anemia during chemotherapy given before maintenance treatment significantly increased the risk of developing anemia during maintenance treatment in patients with platinum-sensitive relapsed ovarian cancer.